Gene editing and many other useful biotechnology tools came from studies of bacteria fighting off viral invaders. But ...

the biotech would push forward CRISPR-based drugs for a series of liver and brain diseases, beginning by filing for a first trial in under two years. It was, suffice to say, bold. Arbor had yet ...

The study was led by Feng Zhang, a core institute member at the Broad and an Investigator at the McGovern Institute for Brain Research at MIT. "As CRISPR therapies enter the clinic, there is a ...

Arbor was co-founded in 2016 by gene-editing pioneer Feng Zhang, who played a leading role in developing the gene editing tool CRISPR/Cas9. Zhang has helped start other Boston-area companies like ...

CRISPR-Cas9 pioneer presented with National Medal of Technology and Innovation in White House awards ceremony China-born biologist Zhang Feng has been awarded the United States' highest honour for ...

and Feng Zhang of the Broad Institute of MIT and Harvard—the three discoverers of the CRISPR-Cas9 system’s utility in gene editing—plus dozens of other big names in genome science,” Akst wrote. In ...

Critics have harsh words for the Broad Institute’s Eric Lander and Cell over a recent perspective piece describing the history of CRISPR. Furthermore ... in the patent dispute with the Broad’s Feng ...

"This is a very versatile RNA-guided system with a lot of diverse functionalities," says Feng Zhang ... Previously, Zhang's ...

View Full Profile. Learn about our Editorial Policies. The first patent for the use of CRISPR to edit eukaryotic genomes was awarded to Zhang in spring 2014, but Doudna—along with Emmanuelle ...